Search for: [Abstract = "ilu re with a high risk of complications and involving significant human resources. lt is implemented in the face of exhaustion of other treatment methods. ECMO is not per se a therapeutic method but rather a bridging method to gain time for damaged organs to recover. The first reports from Wuhan on COVID\-19 patients requiring ECMO indicated an 83% mortality rate. The primary criterion determining eligibility for ECMO therapy is the potentia I reversibility of the process that leci to lungfailure. Among all patients hospitalized in the University Hospital in Cracow due to severe respiratory failure caused by COVID\-19, 36 were qualified for ECMO therapy. 10 patients survived, including 2 who received lung transplants, 26 patients died \(mortality rate of 72.2%\). The leading causes of death in this group of patients were hematological disorders resulting in CNS bleeding and septic shock caused by bacterial superinfection. 20 patients \(56%\) required continuous rena\! replacement therapy \(CRRT\). The average duration of ECMO the rapy was 19.1 days. In 25% of patients, oxygenator dysfu nction necessitated its replacement. This added to the cost of treatment and increased the staff's workload. ECMO therapy was associated with a high mortality rate, yet post\-ECMO survivor's quality of,life show that the therapy can be valuable in young, non\-morbid patients."]

Number of results: 1